<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04253912</url>
  </required_header>
  <id_info>
    <org_study_id>VBP-245-WART2A</org_study_id>
    <nct_id>NCT04253912</nct_id>
  </id_info>
  <brief_title>Topical 2% Povidone-Iodine Gel in Verruca Vulgaris</brief_title>
  <official_title>A Phase 2, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Study to Evaluate Topical 2% Povidone-Iodine Gel (VBP-245) in Subjects With Verruca Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veloce BioPharma LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veloce BioPharma LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled phase 2 study in&#xD;
      subjects 8 years of age and older who present with verruca vulgaris (common warts) and desire&#xD;
      treatment. Subjects may have up to a total of 6 common warts located on their trunk or&#xD;
      extremities that will be treated with study medication and followed throughout the study&#xD;
      protocol therapy. All warts will be treated two times per day (BID) for12 weeks.&#xD;
      Approximately 90 subjects will be enrolled in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 12, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Actual">January 5, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in wart diameter (mm)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of wart</measure>
    <time_frame>12 weeks</time_frame>
    <description>Wart diameter = 0 mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Application Site Reaction Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Warts</condition>
  <arm_group>
    <arm_group_label>VBP-245</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical 2% Povidone-Iodine Gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Gel (no Povidone-Iodine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VBP-245</intervention_name>
    <description>2% Povidone-Iodine Gel</description>
    <arm_group_label>VBP-245</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Gel (no Povidone-Iodine)</intervention_name>
    <description>Placebo Gel (no Povidone-Iodine)</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is able to comprehend and is willing to sign an informed consent/assent for&#xD;
             participation in this study.&#xD;
&#xD;
          -  Male or female â‰¥ 8 years old.&#xD;
&#xD;
          -  Subject has a clinical diagnosis of verruca vulgaris (common warts).&#xD;
&#xD;
          -  Subject has up to 6 warts located on the trunk or extremities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has clinically atypical warts on the trunk or extremities.&#xD;
&#xD;
          -  Subject is immunocompromised (e.g., due to chemotherapy, systemic steroids, genetic&#xD;
             immunodeficiency, transplant status, etc.)&#xD;
&#xD;
          -  Subject has periungual, subungual, genital, anal, mosaic, plantar, flat, or filiform&#xD;
             wart identified as a wart for study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Barone, MD</last_name>
    <role>Study Director</role>
    <affiliation>Veloce BioPharma LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veloce BioPharma Clinical Trial Site</name>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veloce BioPharma Clinical Trial Site</name>
      <address>
        <city>Plymouth Meeting</city>
        <state>Pennsylvania</state>
        <zip>19462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veloce BioPharma Clinical Trial Site</name>
      <address>
        <city>Sugarloaf</city>
        <state>Pennsylvania</state>
        <zip>18429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veloce BioPharma Clinical Trial Site</name>
      <address>
        <city>Upper Saint Clair</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veloce BioPharma Clinical Trial Site</name>
      <address>
        <city>Fort Mill</city>
        <state>South Carolina</state>
        <zip>29708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veloce BioPharma Clinical Trial Site</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veloce BioPharma Clinical Trial Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Aggregate data will be shared with study investigators.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

